🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

198 results for “Novartis Ophthalmics Europe” Clear

  1. -, -, ERYTHROPOIETIN , DANAZOL , VAY736, -, ENTECAVIR , Placebo to VAY736 150 mg/1 mL concentrate for solution for infusion, -, -

    Novartis Ophthalmics Europe

    warm autoimmune haemolytic anaemia (wAIHA)

    phase 3 small molecule active

    1 trial

  2. -, DOCETAXEL , JDQ443

    Novartis Ophthalmics Europe

    Advanced non-small cell lung cancer harboring the KRAS G12C mutation

    phase 3 small molecule active

    1 trial

  3. -, Placebo to ianalumab 150 mg/1 mL concentrate for solution for infusion, -, ENTECAVIR , -, ELTROMBOPAG, -, ELTROMBOPAG, ELTROMBOPAG, VAY736, -, ELTROMBOPAG

    Novartis Ophthalmics Europe

    Primary immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  4. ABIRATERONE ACETATE, ABIRATERONE ACETATE, ENZALUTAMIDE, ABIRATERONE ACETATE, Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation, ENZALUTAMIDE, ENZALUTAMIDE

    Novartis Ophthalmics Europe

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  5. ALPELISIB, FULVESTRANT, ALPELISIB, Placebo to BYL719 50 mg film-coated tablet Light pink Placebo to BYL719 200 mg film-coated tablet Light red

    Novartis Ophthalmics Europe

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  6. ASCIMINIB HYDROCHLORIDE, ASCIMINIB

    Novartis Ophthalmics Europe

    Chronic Myelogenous Leukemia in chronic phase (CML-CP)

    phase 3 small molecule active

    1 trial

  7. ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, Placebo to KJX839 (Inclisiran), ATORVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN

    Novartis Ophthalmics Europe

    Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]) of recent onset.

    phase 3 small molecule active

    1 trial

  8. BAF312, FINGOLIMOD HYDROCHLORIDE, BAF312, BAF312, Placebo to Ofatumumab (OMB157) [Kesimpta], BAF312, OFATUMUMAB, BAF312, Placebo to Siponimod (BAF312) [Mayzent] film-coated tablets, Placebo to Fingolimod (FTY720) [Gilenya] 0.25mg & 0.5mg, FINGOLIMOD HYDROCHLORIDE

    Novartis Ophthalmics Europe

    Multiple Sclerosis in pediatric patients

    phase 3 small molecule active

    1 trial

  9. BYL719, BYL719, Placebo to BYL719 125 mg film-coated tablets, Placebo to BYL719 200 mg film-coated tablets, Placebo to BYL719 50 mg film-coated tablets, BYL719, BYL719, BYL719

    Novartis Ophthalmics Europe

    lymphatic malformations associated with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  10. Bion 1301/FUB523

    Novartis Ophthalmics Europe

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  11. CANAKINUMAB, PEMETREXED

    Novartis Ophthalmics Europe

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  12. CPI-0610, CPI-0610

    Novartis Ophthalmics Europe

    Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)

    phase 3 small molecule active

    1 trial

  13. DASATINIB, IMATINIB, BOSUTINIB, DASATINIB, NILOTINIB, BOSUTINIB, DASATINIB, DASATINIB, NILOTINIB, DASATINIB, IMATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE

    Novartis Ophthalmics Europe

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  14. DEXAMETHASONE , FLUDARABINE , CISPLATIN , OXALIPLATIN , CARBOPLATIN , LENALIDOMIDE , RITUXIMAB , TOCILIZUMAB , CYCLOPHOSPHAMIDE , BENDAMUSTINE , TISAGENLECLEUCEL, IFOSFAMIDE , MELPHALAN , CYTARABINE , CARMUSTINE , IBRUTINIB , ETOPOSIDE , GEMCITABINE

    Novartis Ophthalmics Europe

    Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

    phase 3 small molecule active

    1 trial

  15. ENTECAVIR , VAY736, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled pen, TENOFOVIR ALAFENAMIDE , -, VAY736, TENOFOVIR DISOPROXIL

    Novartis Ophthalmics Europe

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  16. EVEROLIMUS

    Novartis Ophthalmics Europe

    Refractory seizures associated with tuberous sclerosis complex

    phase 3 small molecule active

    1 trial

  17. Flucelvax Tetra - suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes), Pneumovax 23 oldatos injekció e

    Novartis Ophthalmics Europe

    Relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  18. GOSERELIN, RIBOCICLIB, ANASTROZOLE, LETROZOLE

    Novartis Ophthalmics Europe

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  19. Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Novartis Ophthalmics Europe

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  20. INCLISIRAN, -

    Novartis Ophthalmics Europe

    Familial hypercholsterolemia

    phase 3 small molecule active

    1 trial

  21. INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial

    Novartis Ophthalmics Europe

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  22. INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial

    Novartis Ophthalmics Europe

    homozygous familial hypercholesterolemia

    phase 3 small molecule active

    1 trial

  23. IPTACOPAN

    Novartis Ophthalmics Europe

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  24. IPTACOPAN

    Novartis Ophthalmics Europe

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources